[Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Twenty-seven patients with advanced ovarian cancer were treated with CAPF therapy consisting of CPA, ADM, CPDD, and 5-FU. Twenty patients were evaluable for responses. Fourteen patients (70%) had a complete (6 patients) or partial response (8 patients). The median survival time for responders was 12.0+ months and 4.0 for non-responders. Leukopenia and renal toxicity were dose limiting factors. A second-look operation was performed in 12 patients who had favorable results from CAPF. A combined modality with CAPF and second-look operation seemed to be promising.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D012086:Reoperation
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil